



(11)

EP 1 999 148 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)

Corrections, see

Bibliography INID code(s) 73

(51) Int Cl.:

C07K 16/00 ^(2006.01) **C12P 21/08** ^(2006.01)

C07K 1/00 ^(2006.01) **C07K 16/28** ^(2006.01)

C07K 16/46 ^(2006.01) **A61K 39/395** ^(2006.01)

A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:

05.03.2014 Bulletin 2014/10

(86) International application number:

PCT/US2007/005883

(45) Date of publication and mention

of the grant of the patent:

25.12.2013 Bulletin 2013/52

(87) International publication number:

WO 2007/103469 (13.09.2007 Gazette 2007/37)

(21) Application number: **07752572.3**

(22) Date of filing: **06.03.2007**

(54) **HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE**

HUMANISIERTE ANTI-CD22-ANTIKÖRPER UND IHRE VERWENDUNG FÜR DIE BEHANDLUNG VON KREBS, TRANSPLANTATIONEN UND AUTOIMMUNERKRANKUNGEN

ANTICORPS HUMANISÉS DIRIGÉS CONTRE L'ANTIGÈNE CD22 ET LEUR UTILISATION À DES FINS THÉRAPEUTIQUES EN ONCOLOGIE, AINSI QUE DANS LE CADRE DE TRANSPLANTATIONS ET DE MALADIES AUTO-IMMUNES

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated Extension States:

AL BA HR MK RS

(74) Representative: **Gibbs, Richard**

Marks & Clerk LLP

Aurora

120 Bothwell Street

Glasgow G2 7JS (GB)

(30) Priority: **06.03.2006 US 779804 P**

(43) Date of publication of application:

10.12.2008 Bulletin 2008/50

(56) References cited:

WO-A1-94/27638 WO-A2-03/093320

WO-A2-2007/103470 US-A1- 2003 202 975

US-A1- 2004 001 828 US-A1- 2004 001 828

US-A1- 2005 118 182

(60) Divisional application:

12175725.6 / 2 540 741

13170804.2 / 2 650 306

(73) Proprietor: **MedImmune, LLC**

Gaithersburg, MD 20878 (US)

- **TUSCANO JOSEPH M ET AL: "Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts." BLOOD 1 MAY 2003, vol. 101, no. 9, 1 May 2003 (2003-05-01), pages 3641-3647, XP002540281 ISSN: 0006-4971**

(72) Inventors:

- **JONES, Tarran**
Hertfordshire WD7 8AG (GB)

- **WILLIAMS, David, G.**
Surrey KT18 7LY (GB)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 999 148 B8

- O'DONNELL ROBERT T ET AL: "Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy." CANCERIMMUNOLOGY, IMMUNOTHERAPY : CII OCT 2009, vol. 58, no. 10, October 2009 (2009-10), pages 1715-1722, XP002540282 ISSN: 1432-0851
- ENGEL P ET AL: "THE SAME EPITOPE ON CD22 OF LYMPHOCYTES MEDIATES THE ADHESION OF ERYTHROCYTES, T AND B LYMPHOCYTES, NEUTROPHILS, AND MONOCYTES" JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 150, no. 11, 1 June 1993 (1993-06-01) , pages 4719-4732, XP000999233 ISSN: 0022-1767
- ENGEL P. ET AL.: 'IDENTIFICATION OF THE LIGAND-BINDING DORMAINS OF CD22, A MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY THAT UNIQUELY BINDS A SIALIC ACID-DEPENDENT LIGAND' J. EXP. MED. vol. 181, no. 4, 01 April 1995, pages 1581 - 1586, XP001005276